Insurance plans offered through the Affordable Care Act are placing fewer drugs on the specialty tier of formularies than they were 2 years prior, according to a new study from Avalere.
Insurance plans offered through the Affordable Care Act are placing fewer drugs on the specialty tier of formularies than they were 2 years prior, according to a new study from Avalere.
In a national survey reviewing 2016 silver-level exchange plans across 20 classes of medications, including a mixture specialty and primary care drugs, Avalere discovered that plans were less likely to place all drug options for complex diseases—like HIV, cancer, and multiple sclerosis—on the highest tier of formularies than they had in 2014 and 2015.
In addition to HIV, cancer, and multiple sclerosis, the researchers noted that there were 2 other classes, for which some plans place all drugs in the class on the highest tier. Half of all silver-level plans placed every drug from the antiangiogenics on the specialty tier in 2016. Nearly one-third of these plans placed all covered multiple sclerosis drugs on the specialty tier as well.
The sharpest decline was for molecular target inhibitors. For these 3 classes, 2016 shows a reversal of the sharp increase in this type of tiering structure that occurred between 2014 and 2015.
The advantage to dispersing drugs throughout different tiers of a formulary could mean more access to drugs with less out-of-pocket costs to patients.
According to the report, while CMS has issued guidance discouraging plans from placing all drugs used to treat a condition on the highest tier without regard to the cost of the medication, the federal government has yet to provide a tool for regulators to evaluate benefit designs.
“Insurance departments across the country need tools to ensure CMS’s guidance is implemented,” said Kelly Brantley, director at Avalere. “A tool that evaluates formulary tier placement could help ensure patient access.”
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More